Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290326 · ClinicalTrials.gov registry record · NA
tACS for Amyloid-β Reduction in Alzheimer's Disease
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT03290326: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03290326 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03290326, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. The evidence suggests that both amyloid and tau play a critical role in AD and interventions that reliably and safely decrease the intracerebral burden of amyloid or tau could potentially be of marked clinical importance. Currently, therapeutic options are very limited and while there are pharmacologic interventions that transiently improve cognitive function, there are no treatments that alter disease progression. The current study seeks to use a novel therapeutic intervention that uses noninvasive brain stimulation to target amyloid in the brain. The investigators anticipate this will decrease the amyloid levels in the brain, as evidence by Positron Emission Tomography (PET) imaging.
Interventions
- DEVICE Transcranial Alternating Current Stimulation (tACS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2019-05-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03290326
The ClinicalTrials.gov registry entry for NCT03290326 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transcranial Alternating Current Stimulation (tACS) is the first listed.
NCT03290326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03290326 about?
NCT03290326 is a clinical study titled "tACS for Amyloid-β Reduction in Alzheimer's Disease". Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. The evidence suggests that both amyloid and tau play a critical role in AD and interventions that reliably and safely decrease the intracer...
What is the current status of trial NCT03290326?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2017-11-27. Estimated completion is 2019-05-14.
What interventions are being tested in trial NCT03290326?
The interventions under investigation include: Transcranial Alternating Current Stimulation (tACS) (DEVICE).
Who is sponsoring clinical trial NCT03290326?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.